
New property is valued at $323 million
New property is valued at $323 million
Center will feature a $1.4 billion investment plan
Production capacity for the contract manufacturer is expected to more than triple
Will benefit CDMO’s Denmark and Texas locations
With a cost of approximately $514 million, expected completion is 2026
Cheshire facility will offer plasmid DNA production, CGT development
Marks the CDMO’s second plant in the country
Containers to potentially be operational by next year, 2024 at the latest
CDMO looks to combat cancer at lower doses
Agency will be reviewing laboratory study and CMC data on the bivalent jab that targets two strains of the SARS-CoV-2 virus
CDMO’s Costa Mesa location can start tackling oncology and rare disease treatment
Partnership aims to compare reproducibility and comparability between different suspension bioreactors
New service offering is GMP compliant, with single-use fermentation capacity of up to 300 L
Focus on operational excellence is playing a major role in this effort, company says
CDMO’s Ireland campus will increase in capacity by 50% as a result
Will serve as a hub, as company aims for growth in the European region
GMP facility allows for an increase in AAV vector production
A conversation with EY life sciences leaders Jim Welch and Jay Welsh
The packaging and shipping of dangerous goods (DG) adds further challenges to the distribution pressures brought about by the pandemic
The crucial link of labeling and packaging in the pharma supply chain has its glory, but is not without its set of obstacles amid current market and global challenges
Project is expected to grow CRDO’s capacity by over 150,000 square feet
Facility, with expected completion of 2025, will specialize in mRNA-based therapies
As a result of new production area, India site’s total production capacity rises from 3 to 4.5 billion doses
Investment will grow manufacturing capabilities at Winchester site
East Syracuse site will serve as a hub for company’s US biologics CDMO business